Legislation and Policy Seem To Leave Patient Care Behind
April gave us twenty articles. Every single one circled the same fault line: the growing distance between what patients need and what the system delivers. Denial rates are climbing. Drug pricing reform bills are stacking up in statehouses. A $13 billion Medicare Advantage bump that rewards the same plans patients keep fighting. And a federal health governance apparatus that looks less like oversight and more like a contact sport.
I read every one of these stories through a single lens: what does this mean for the person sitting in the waiting room, the caregiver on hold with the insurance company, the advocate trying to move the needle? That lens shapes everything below.
Here is what April told us.
State legislatures drove the conversation in April, and they did it with a clarity that federal agencies have failed to match. Tennessee, Virginia, and a growing list of states moved aggressively on PBM reform and drug pricing transparency. Meanwhile, at the federal level, the ACIP charter rewrite and No Surprises Act court battles signaled that the rules of engagement around patient protections remain very much unsettled.
Tennessee’s Fair Rx Act advanced with bipartisan support, requiring PBMs to be transparent about pricing and limiting spread pricing. Virginia’s PDAB bill followed a similar trajectory. These state-level moves now represent the most concrete policy progress on drug pricing in the country, outpacing Congress on every measurable front.
Express Scripts reached a deal with the FTC, but the terms raise more questions than they answer. The settlement addresses specific rebate practices without touching the structural conflicts of interest that drive PBM behavior. Advocates should watch the enforcement mechanisms closely.
RFK Jr.’s rewrite of the ACIP charter restructures how vaccine recommendations reach the public. The practical effect: fewer independent scientists in the room when those decisions get made. For patient advocates working in immunization access, this immediately changes the landscape.
No Surprises Act court rulings in April split on key enforcement provisions. Two federal courts reached different conclusions on arbitration timelines, creating a patchwork that leaves providers and patients in different positions depending on geography.
The pattern here matters more than any single bill. States have stopped waiting for Washington. That creates opportunity for advocates who can work at the state level, and real risk for those who only track federal policy.
April’s cost-of-care stories landed hard. A $13 billion CMS bump to Medicare Advantage plans. Hospitals in Virginia are suing patients over unpaid bills. And an IQVIA report that put a number on what advocates have known for years: 70% of prior authorization requests are denied on the first pass.
IQVIA’s data showed a 70% initial denial rate for prior authorizations across commercial plans. That number should be tattooed on the forehead of every health plan executive who claims the process protects patients. It protects margins. Full stop.
CMS approved a $13 billion increase in Medicare Advantage payments for 2026, despite years of documented upcoding and inflated risk scores. The Government Accountability Office repeatedly flagged these issues. CMS funded the plans anyway.
Virginia hospitals filed lawsuits against patients with outstanding medical debt, including patients who qualified for charity care but never received application materials. The reporting revealed systemic failures in financial screening processes at multiple health systems.
HHS convened a drug pricing summit in late April that brought together manufacturers, PBMs, and patient groups. The summit produced no binding commitments, but it surfaced internal disagreements within the administration over the scope and pace of pricing reform.
The through line across these stories: the system continues to extract maximum revenue from the people least equipped to push back. Advocates need hard numbers, such as IQVIA data, to make the case. Outrage without evidence changes nothing.
Two stories in April forced a conversation about who the healthcare system actually serves. Half of cancer patients never receive the genomic tests that could change their treatment trajectory. Provider-insurer disputes continued to leave patients caught in the crossfire, losing access to doctors and networks with little warning and less recourse.
A study published in mid-April found that roughly 50% of cancer patients eligible for genomic testing never receive it. The gap tracks closely with race, income, and geography. Patients in rural areas and patients on Medicaid face the steepest barriers to access.
Provider-insurer contract disputes disrupted care for thousands of patients in at least four states during April. In each case, patients learned about network changes after the fact, often through denial letters rather than proactive notification.
Oscar Health’s cancer treatment denial made national headlines when internal documents revealed that the insurer’s algorithm flagged certain oncology protocols for automatic review. The case became a flashpoint for broader concerns about AI-driven utilization management.
These stories share a common thread: information asymmetry. Patients lack the data, the notice, and the navigational support to protect their own interests. Closing that gap remains the single most impactful thing advocacy organizations can do.
April’s technology stories split into two camps: companies betting billions on AI-driven healthcare, and a quiet resurgence in rare disease R&D that could reshape how we think about underserved therapeutic areas.
UnitedHealth Group committed $3 billion to AI infrastructure aimed at claims processing, clinical decision support, and network management. The investment dwarfs anything competitors have announced and raises legitimate questions about conflicts of interest when the same company processes claims and deploys the AI that adjudicates them.
Eli Lilly launched Foundayo, its direct-to-consumer GLP-1 product, using a distribution model that bypasses traditional pharmacy channels. The launch rewrites assumptions about how branded drugs reach patients and how PBMs factor into the equation.
Rare neurology R&D saw a notable uptick in April, with three mid-stage pipeline assets advancing in conditions affecting fewer than 50,000 patients in the U.S. The investment signals that orphan drug economics still attract capital, even as broader pharma portfolios shift toward large-population indications.
The technology story in healthcare keeps circling the same question: who benefits? When UnitedHealth deploys AI to process claims faster, the efficiency gains flow to the balance sheet first. When Lilly bypasses PBMs, patients may pay less or simply pay differently. Advocates need to track outcomes, not announcements.
Twenty articles. Four categories. One takeaway: April 2026 confirmed that the healthcare system rewards those who show up with data, persistence, and a clear ask. The policy window at the state level has never been wider. The cost-of-care data has never been more damning. The technology investments have never been larger or more consequential.
The question for advocates heading into May: are you using this moment, or watching it pass?
If you want to better understand how your organization views your advocacy function, head on over to the Advocacy Influence Diagnostic. Free, anonymous, and takes less than 5 minutes to complete. Gain a deeper understanding of your organization’s view of the advocacy function through the Advocacy Value Index and the Advocacy Strategic Risk Score. The results will inform you how you can improve your function’s impact within your organization. Upon completion, you can opt in to receive a complimentary strategy session with Matt Toresco to discuss your results and next steps.
All articles noted in this month’s ADVOCATE BRIEF, and others collected in Matt Toresco’s monthly PEST, can be found at intelligence.archo.io.
Today’s blog post consisted of insights from the following sources:
IQVIA Prior Authorization Denial Rate Analysis, April 2026
Tennessee Fair Rx Act (SB 1247), Committee Proceedings
Virginia PDAB Drug Pricing Bill, April 2026 Session
Express Scripts / FTC Settlement Terms, April 2026
CMS Medicare Advantage Rate Notice, CY2026 Final
GAO Report on Medicare Advantage Risk Score Adjustments
Virginia Hospital Medical Debt Litigation, Multiple Filings
HHS Drug Pricing Summit Proceedings, April 28, 2026
Genomic Testing Access Study, Published April 2026
Oscar Health Utilization Management Internal Review
UnitedHealth Group AI Investment Announcement, Q1 2026
Eli Lilly Foundayo Launch and Distribution Model
RFK Jr. ACIP Charter Revision, Federal Register April 2026
No Surprises Act Arbitration Rulings, April 2026
Rare Neurology Pipeline Update, April 2026
Originally published in The Archo Advocate Brief.
